CDC: RSV Vaccine Recommended for Older PeopleCENTERS for Disease Control & Prevention (U.S.)RESPIRATORY syncytial virus infection vaccinesOLDER peopledoi:10.1001/jama.2023.12537Harris, EmilyJAMA: Journal of the American Medical Association
此次CDC公布的数据通过新疫苗监测网络(New Vaccine Surveillance Network)评估所得,内容涉及2023年10月1日至2024年2月29日间,首个RSV季节中Beyfortus预防RSV相关住院治疗有效性的分析。分析显示,在699名因急性呼吸道疾病住院的婴儿中,有59名(8%)在症状出现≥7天前接受了Beyfortus。Beyfortus对于预防RSV相关住院治疗的...
此次CDC公布的数据通过新疫苗监测网络(New Vaccine Surveillance Network)评估所得,内容涉及2023年10月1日至2024年2月29日间,首个RSV季节中Beyfortus预防RSV相关住院治疗有效性的分析。分析显示,在699名因急性呼吸道疾病住院的婴儿中,有59名(8%)在症状出现≥7天前接受了Beyfortus。Beyfortus对于预防RSV相关住院治疗的...
The U.S. Centers for Disease Control and Prevention have recommended the first-ever vaccine designed to protect infants from respiratory syncytial virus. The CDC said the Pfizer vaccine should be taken during weeks 32 and 36 of pregnancy.Sept 23, 2023 ...
RSV vaccine & mAB snapshot Airfinity预计,根据CDC的新建议,到2030年,美国RSV疫苗市场的总价值可能下降64%,老年人疫苗市场的预期价值从47亿美元降至17亿美元。去年,美国老年人RSV疫苗市场规模为24亿美元,但预计今年将降至22亿美元。新建议将导致符合条件的接种人群减少44%,至4600万人。
Originally, Arexvy was the only FDA-approved RSV vaccine for older adults. However, since this approval, two other RSV vaccines have come to market. The Pfizer RSV vaccine, Abrysvo, is also a protein subunit vaccine. The CDC estimates the effectiveness of protein subunit RS...
https://www.gov.uk/government/news/new-rsv-vaccine-could-prevent-5000-infant-hospitalisations#_ftn1 https://www.reuters.com/business/healthcare-pharmaceuticals/gsk-pfizer-rsv-vaccine-sales-fall-us-millions-fewer-people-line-up-2024-10-08/ ...
An RSV vaccine has been approved by the FDA and the CDC will hold a meeting on the new injections on Thursday.
(RSV) vaccines from GSK and Pfizer for people aged 60 years and older, according to a recent CDC statement. The vaccines should be administered using shared clinical decision-making, meaning individuals can receive a single dose of the vaccine based on conversations with their health care ...
Grannis and colleagues used a test-negative study designed to compare the effectiveness of the RSV vaccine in adults aged 60 years or older admitted to a hospital or who had an ED visit for an RSV-like illness between Oct. 1, 2023, and March 31, 2024. The analysi...